These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19715956)

  • 1. Effect of different pharmacologic agents to reverse severe pulmonary hypertension among end-stage heart failure patients.
    Torres Macho J; Delgado Jimenez JF; Sanz Salvo J; Gonzalez Mansilla A; Sanchez Sanchez V; Gamez Diez S; Escribano Subias P; Saenz de la Calzada C
    Transplant Proc; 2009; 41(6):2477-9. PubMed ID: 19715956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension.
    Givertz MM; Hare JM; Loh E; Gauthier DF; Colucci WS
    J Am Coll Cardiol; 1996 Dec; 28(7):1775-80. PubMed ID: 8962566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study.
    von Scheidt W; Costard-Jaeckle A; Stempfle HU; Deng MC; Schwaab B; Haaff B; Naegele H; Mohacsi P; Trautnitz M;
    J Heart Lung Transplant; 2006 Sep; 25(9):1070-6. PubMed ID: 16962468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between two drugs on the hemodynamic evaluation of pulmonary hypertension prior to heart transplantation.
    Mogollón Jiménez MV; Escoresca Ortega AM; Hinojosa Pérez R; Lage Gallé E; Herruzo Avilés A; Sobrino Márquez M; Frutos López M; Romero Rodríguez N; Pérez de la Yglesia R; Martínez Martínez A
    Transplant Proc; 2008 Nov; 40(9):3009-11. PubMed ID: 19010174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-existing pulmonary hypertension in patients with end-stage heart failure: impact on clinical outcome and hemodynamic follow-up after orthotopic heart transplantation.
    Goland S; Czer LS; Kass RM; De Robertis MA; Mirocha J; Coleman B; Capelli C; Raissi S; Cheng W; Fontana G; Trento A
    J Heart Lung Transplant; 2007 Apr; 26(4):312-8. PubMed ID: 17403470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible pulmonary hypertension in heart transplant candidates: to transplant or not to transplant.
    Klotz S; Wenzelburger F; Stypmann J; Welp H; Drees G; Schmid C; Scheld HH
    Ann Thorac Surg; 2006 Nov; 82(5):1770-3. PubMed ID: 17062245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does pretransplant left ventricular assist device therapy improve results after heart transplantation in patients with elevated pulmonary vascular resistance?
    Liden H; Haraldsson A; Ricksten SE; Kjellman U; Wiklund L
    Eur J Cardiothorac Surg; 2009 Jun; 35(6):1029-34; discussion 1034-5. PubMed ID: 19211259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of prostaglandin E1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension.
    Murali S; Uretsky BF; Armitage JM; Tokarczyk TR; Betschart AR; Kormos RL; Stein KL; Reddy PS; Hardesty RL; Griffith BP
    J Heart Lung Transplant; 1992; 11(4 Pt 1):716-23. PubMed ID: 1498137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-transplant reversible pulmonary hypertension predicts higher risk for mortality after cardiac transplantation.
    Butler J; Stankewicz MA; Wu J; Chomsky DB; Howser RL; Khadim G; Davis SF; Pierson RN; Wilson JR
    J Heart Lung Transplant; 2005 Feb; 24(2):170-7. PubMed ID: 15701433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of reversible pulmonary hypertension on outcomes after heart transplantation.
    Drakos SG; Kfoury AG; Gilbert EM; Horne BD; Long JW; Stringham JC; Campbell BA; Renlund DG
    J Heart Lung Transplant; 2007 Apr; 26(4):319-23. PubMed ID: 17403471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates.
    Radovancevic B; Vrtovec B; Thomas CD; Croitoru M; Myers TJ; Radovancevic R; Khan T; Massin EK; Frazier OH
    J Heart Lung Transplant; 2005 Jun; 24(6):690-5. PubMed ID: 15949728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing pulmonary hypertension in heart transplantation: meeting the challenge.
    Coe PF
    Crit Care Nurse; 2000 Apr; 20(2):22-8; quiz 29-30. PubMed ID: 11873750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside.
    Kieler-Jensen N; Lundin S; Ricksten SE
    J Heart Lung Transplant; 1995; 14(3):436-43. PubMed ID: 7654728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markers of pulmonary hypertension in potential candidates to heart transplantation.
    Wierzbicki K; Przybyłowski P; Sobczyk D; Konstanty J; Kapelak B; Drwiła R; Krochin M; Podolec P; Wójcik S; Marek G; Wróbel K; Piatek J; Rudziński P; Sadowski J
    Przegl Lek; 2006; 63(12):1263-8. PubMed ID: 17642136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled nitric oxide through a noninvasive ventilation device to assess reversibility of pulmonary hypertension in selecting recipients for heart transplant.
    Fojón S; Fernández-González C; Sánchez-Andrade J; López-Pérez JM; Hermida LF; Rodríguez JA; Juffé A
    Transplant Proc; 2005 Nov; 37(9):4028-30. PubMed ID: 16386617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension.
    Braun S; Schrötter H; Schmeisser A; Strasser RH
    Int J Cardiol; 2007 Jan; 115(1):67-72. PubMed ID: 16797747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of chronic sildenafil use on pulmonary hemodynamics and clinical outcomes in heart transplantation.
    Pons J; Leblanc MH; Bernier M; Cantin B; Bourgault C; Bergeron S; Proulx G; Morin J; Nalli C; O'Connor K; Chateauvert N; Sénéchal M
    J Heart Lung Transplant; 2012 Dec; 31(12):1281-7. PubMed ID: 23127754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of reversibility of pulmonary hypertension in cardiac transplant recipients in the first postoperative year.
    Chau EM; Bailey KR; Mahoney DW; Frantz RP; McGregor CG; Daly RC; Edwards BS; Olson LJ; Rodeheffer RJ
    Circulation; 1996 Nov; 94(9 Suppl):II267-72. PubMed ID: 8901758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil.
    Melenovsky V; Al-Hiti H; Kazdova L; Jabor A; Syrovatka P; Malek I; Kettner J; Kautzner J
    J Am Coll Cardiol; 2009 Aug; 54(7):595-600. PubMed ID: 19660688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension.
    Perez-Villa F; Cuppoletti A; Rossel V; Vallejos I; Roig E
    Clin Transplant; 2006; 20(2):239-44. PubMed ID: 16640533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.